Verrica Pharmaceuticals, Inc.

As of November 7, 2022, Verrica Pharmaceuticals is considered risky and overvalued, with unfavorable financial metrics and a one-year stock return of -78.16%, significantly underperforming the S&P 500's 17.14%.

As of November 7, 2022, Verrica Pharmaceuticals is considered overvalued and categorized as "risky" due to negative financial ratios, including a price-to-book value of -3.05, a negative return on equity, and significant underperformance compared to peers and the S&P 500.

As of June 2, 2025, Verrica Pharmaceuticals, Inc. exhibits a mildly bearish trend due to bearish daily moving averages and monthly MACD signals, despite some weekly indicators showing mild bullishness.

As of March 2022, the management team of Verrica Pharmaceuticals, Inc. includes Chairman Paul Manning, CEO Ted White, and Directors Lawrence Eichenfield, Diem Nguyen, Sean Stalfort, Craig Ballaron, and Mark Prygocki. They oversee the company's strategic direction and operations.

Verrica Pharmaceuticals, Inc. is a clinical-stage medical dermatology company focused on developing treatments for skin diseases. As of March 2025, it reported net sales of $3 million and a net loss of $10 million, with a market cap of $59.40 million.

As of Jun 18, Verrica Pharmaceuticals, Inc. has a market capitalization of 59.40 million and reported net sales of 7.18 million with a net profit of -65.99 million over the latest four quarters. Shareholder's funds are at -9.86 million, and total assets amount to 54.62 million.